Premium
Postmarketing Surveillance: Curriculum for the Clinical Pharmacologist. Part II: Clinical and Regulatory Considerations
Author(s) -
Johnson Joyce M.,
Tanner L. Ann
Publication year - 1993
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1993.tb01938.x
Subject(s) - postmarketing surveillance , clinical pharmacology , medicine , context (archaeology) , curriculum , drug , drug class , pharmacology , perspective (graphical) , clinical trial , pharmacodynamics , medical education , engineering ethics , pharmacokinetics , psychology , adverse effect , computer science , engineering , paleontology , pedagogy , artificial intelligence , biology
This is the second of a two‐part series that develops a curriculum on postmarketing surveillance. With the ongoing emphasis on drug safety and possible earlier marketing of drugs, this becomes an essential element of clinical pharmacology training. The usual educational focus on drug safety is a pharmacokinetic or pharmacodynamic perspective on a specific drug or drug class, perhaps in the context of clinical trial study design and analysis. This curriculum complements this approach and provides an overview of drug safety surveillance from regulatory and epidemiologic perspectives.